Transglutaminase 2

Monoclonal antibody to human TG2 (Beta Barrel 2 Domain, clone XTG18)

(antibody reacts with the Beta Barrel 2 Domain of human transglutaminase 2)

200 µg 365 € available

Art. No. A037
Background info Tissue transglutaminase is a, Ca2+-dependent enzyme (78 kDa) composed by 4 domains:
Beta Sheet Domain (fibronectin binding, ~17 kDa), catalytic Core Domain (Cys-His-Asp catalytic triad, Calcium-binding, GTP/GDP-binding, ~37 kDa), Beta Barrel 1 Domain (GTP/GDP-binding, ~14 kDa) and Beta Barrel 2 Domain (~12 kDa). The inactive GTP-bound enzyme is present in a closed conformation, which upon activation by Ca2+ and substrate binding opens like a pocket knife resulting in a longitudinal open conformation.
Host Mouse
Immunogen Human tissue transglutaminase (full length protein with N-terminal hexahistidin-tag) recombinantly produced in insect cells
Specificity Mouse monoclonal antibody reacts with the Beta Barrel 2 Domain of TG2
Specificity of A037 was determined in western blotting with human transglutaminases (TG1 – TG7, FXIII), TG2 of different species and human TG2 domains recombinantly produced in E. coli.
A037 is specific for the Beta Barrel 2 Domain of TG2. It does not cross-react with other domains of human TG2.
A037 is specific for TG2. It does not cross-react with other human transglutaminases.
A037 is specific for human TG2. It does not cross-react with other TG2 from various species (human, guinea pig, rat, mouse and dog).

A037 recognizes the epitope V604AEVSLQNP612 (see figure below). The epitope was determined using PEPperCHIP® Transglutaminase Microarray (Art. No. P111).

For more information klick here:
Poster presentation at GRC, 2016 (Girona, Spain)
Appearance liquid
Description Protein G-affinity purified mouse monoclonal antibody.
Application Western-Blotting only
Working dilutions Optimal dilutions should be determined by the end user.
E. g. for Western-Blotting: 1 / 500 to 1 / 5,000 should be suitable
Storage Store at 2 – 8 °C
Delivery is possible at ambient temperature
Reference(s) Kanchan et al., Cell. Mol. Life Sci. 2015, 72:3009-35
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • Canceled and rescheduled: Tampere Celiac Disease Symposium 2020

    18.09.2020 - 19.09.2020
    Tampere, Finland

  • 19th International Celiac Disease Symposium

    30.09.2021 - 03.10.2021
    Sorrento, Italy